MNPR Insider Trading

Insider Ownership Percentage: 20.50%
Insider Buying (Last 12 Months): $62,081.20
Insider Selling (Last 12 Months): $1,166,690.00

Monopar Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Monopar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Monopar Therapeutics Share Price & Price History

Current Price: $33.82
Price Change: Price Decrease of -0.83 (-2.40%)
As of 06/12/2025 05:00 PM ET

This chart shows the closing price history over time for MNPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Monopar Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2025Tactic Pharma LlcMajor ShareholderSell33,334$35.00$1,166,690.00822,255View SEC Filing Icon  
10/28/2024Karthik RadhakrishnanCFOBuy1,550$16.25$25,187.501,550View SEC Filing Icon  
6/20/2024Andrew CittadineCOOBuy4,101$3.70$15,173.7037,226View SEC Filing Icon  
6/17/2024Andrew CittadineCOOBuy2,400$4.50$10,800.0030,724View SEC Filing Icon  
6/13/2024Andrew CittadineCOOBuy2,400$4.55$10,920.0025,924View SEC Filing Icon  
6/3/2024Andrew CittadineCOOBuy2,400$3.80$9,120.0021,124View SEC Filing Icon  
5/31/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0018,724View SEC Filing Icon  
5/29/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0013,924View SEC Filing Icon  
11/14/2022Andrew CittadineCOOBuy1,210$15.00$18,150.002,847View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Monopar Therapeutics (NASDAQ:MNPR)

1.83% of Monopar Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Monopar Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2025Jane Street Group LLC10,357$0.38M0.0%N/A0.169%Search for SEC Filing on Google Icon
5/16/2025Goldman Sachs Group Inc.18,480$0.67M0.0%N/A0.302%Search for SEC Filing on Google Icon
5/16/2025ADAR1 Capital Management LLC100,774$3.67M0.7%-22.5%1.648%Search for SEC Filing on Google Icon
5/15/2025OMERS ADMINISTRATION Corp9,000$0.33M0.0%N/A0.147%Search for SEC Filing on Google Icon
5/14/2025Affinity Asset Advisors LLC62,000$2.26M0.2%N/A1.014%Search for SEC Filing on Google Icon
5/14/2025AlphaQuest LLC1,215$44K0.0%N/A0.020%Search for SEC Filing on Google Icon
4/23/2025Gerber LLC5,601$0.20M0.2%N/A0.092%Search for SEC Filing on Google Icon
2/17/2025Point72 Asset Management L.P.167,892$3.69M0.0%N/A2.752%Search for SEC Filing on Google Icon
2/17/2025Janus Henderson Group PLC1,046,899$23.44M0.0%N/A17.162%Search for SEC Filing on Google Icon
2/14/2025RA Capital Management L.P.511,207$11.25M0.1%N/A8.380%Search for SEC Filing on Google Icon
2/14/2025Adage Capital Partners GP L.L.C.599,195$13.18M0.0%N/A9.823%Search for SEC Filing on Google Icon
2/13/2025ADAR1 Capital Management LLC130,037$2.86M0.6%N/A2.132%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC38,596$0.85M0.0%+174.4%0.633%Search for SEC Filing on Google Icon
2/12/2025JPMorgan Chase & Co.2,037$45K0.0%N/A0.033%Search for SEC Filing on Google Icon
10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC28,761$0.17M0.0%+9.0%0.229%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.97,462$0.57M0.0%+116.2%0.775%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp36,001$0.22M0.0%-38.8%0.286%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC26,394$0.16M0.0%N/A0.210%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.11,229$70K0.0%+108.3%0.089%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Monopar Therapeutics logo
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More on Monopar Therapeutics

Today's Range

Now: $33.82
Low: $33.36
High: $35.33

50 Day Range

MA: $36.98
Low: $28.89
High: $44.96

52 Week Range

Now: $33.82
Low: $1.72
High: $54.30

Volume

43,269 shs

Average Volume

37,860 shs

Market Capitalization

$206.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Who are the company insiders with the largest holdings of Monopar Therapeutics?

Monopar Therapeutics' top insider investors include:
  1. Tactic Pharma Llc (Major Shareholder)
  2. Andrew Cittadine (COO)
  3. Karthik Radhakrishnan (CFO)
Learn More about top insider investors at Monopar Therapeutics.

Who are the major institutional investors of Monopar Therapeutics?

Monopar Therapeutics' top institutional shareholders include:
  1. ADAR1 Capital Management LLC — 1.65%
  2. Affinity Asset Advisors LLC — 1.01%
  3. Goldman Sachs Group Inc. — 0.30%
  4. Jane Street Group LLC — 0.17%
  5. OMERS ADMINISTRATION Corp — 0.15%
  6. Gerber LLC — 0.09%
Learn More about top institutional investors of Monopar Therapeutics stock.

Which major investors are selling Monopar Therapeutics stock?

In the previous quarter, MNPR stock was sold by these institutional investors:
  1. ADAR1 Capital Management LLC

Which major investors are buying Monopar Therapeutics stock?

In the previous quarter, MNPR stock was bought by institutional investors including:
  1. Affinity Asset Advisors LLC
  2. Goldman Sachs Group Inc.
  3. Jane Street Group LLC
  4. OMERS ADMINISTRATION Corp
  5. Gerber LLC
  6. AlphaQuest LLC
During the last year, these company insiders have bought Monopar Therapeutics stock:
  1. Tactic Pharma Llc (Major Shareholder)
  2. Andrew Cittadine (COO)
Learn More investors buying Monopar Therapeutics stock.